
Oscar B. Lahoud
Articles
-
Feb 4, 2025 |
ajmc.com | Maggie L. Shaw |Oscar B. Lahoud |Kasey Bond
February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.
-
Sep 18, 2024 |
nature.com | Malin Hultcrantz |Hani Hassoun |Neha Korde |Kylee H. Maclachlan |Sham Mailankody |Urvi A. Shah | +9 more
Letter to the EditorLenalidomide is an immunomodulatory drug that is recommended and widely used as part of induction therapy and maintenance for multiple myeloma (MM) [1]. Lenalidomide maintenance is associated with significantly improved progression-free and overall survival, as shown in several clinical trials and meta-analyses [2,3,4,5,6,7]. Most patients tolerate lenalidomide well; however, fatigue and diarrhea are common side effects in the maintenance phase [3, 7, 8].
-
May 30, 2024 |
nature.com | Andriy Derkach |Bruno Costa |David Chung |Heather Landau |Oscar B. Lahoud |Hani Hassoun | +8 more
AbstractB-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates (ADC). The primary endpoint was severe (grade ≥3) infection incidence. Amongst 256 patients, 92 received CAR-T, 55 BsAb and 109 ADC.
-
May 26, 2024 |
nature.com | Bruno Costa |David Chung |Heather Landau |Oscar B. Lahoud |Gunjan L. Shah |Hani Hassoun | +8 more
AbstractDespite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is limited data regarding the impact of tocilizumab (TCZ) and corticosteroids (CCS) on chimeric antigen receptor (CAR) T-cell efficacy in multiple myeloma (MM). The present study aims to evaluate the prognostic impact of these immunosuppressants in recipients of BCMA- or GPRC5D-directed CAR T cells for relapsed/refractory MM.
-
Jul 25, 2023 |
nature.com | Carlyn Tan |Andriy Derkach |Malin Hultcrantz |Sham Mailankody |Urvi A. Shah |Kylee H. Maclachlan | +7 more
AbstractLenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly diagnosed multiple myeloma, 198 received VRd and 191 received KRd. Median PFS was not reached (NR) in both groups; 5-year PFS was 56% (95%CI, 48–64%) for VRd and 67% (60–75%) for KRd (P = 0.027).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →